J
James A. Bolognese
Researcher at Merck & Co.
Publications - 60
Citations - 8224
James A. Bolognese is an academic researcher from Merck & Co.. The author has contributed to research in topics: Rofecoxib & Placebo. The author has an hindex of 29, co-authored 55 publications receiving 7992 citations. Previous affiliations of James A. Bolognese include Cytel.
Papers
More filters
Journal ArticleDOI
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
Robert S. Bresalier,Robert S. Sandler,Hui Quan,James A. Bolognese,Bettina Oxenius,Kevin J. Horgan,Christopher Lines,Robert H. Riddell,Dion Morton,Angel Lanas,Marvin A. Konstam,John A. Baron +11 more
TL;DR: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk, and cardiovascular mortality was similar in the two groups.
Journal ArticleDOI
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
M. J. S. Langman,Dennis M. Jensen,Douglas J. Watson,Sean E. Harper,Peng-Liang Zhao,Hui Quan,James A. Bolognese,Thomas J. Simon +7 more
TL;DR: Treatment with rofecoxib was associated with a significantly lower incidence of PUBs than treatment with NSAIDs, based on survival analysis of time to first PUB diagnosis, using Pubs that met pre-specified criteria judged by a blinded, external adjudication committee.
Journal ArticleDOI
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Christopher P. Cannon,Sean P. Curtis,Garret A. FitzGerald,Henry Krum,Amarjot Kaur,James A. Bolognese,Alise S. Reicin,Claire Bombardier,Michael E. Weinblatt,Désirée van der Heijde,Erland Erdmann,Loren Laine +11 more
TL;DR: Rates of thrombotic cardiovascular events in patients with arthritis on etoricoxib are similar to those in patients on diclofenac with long-term use of these drugs.
Journal ArticleDOI
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
Loren Laine,Sean E. Harper,Thomas J. Simon,Richard Bath,John F. Johanson,Howard Schwartz,Steven H. Stern,Hui Quan,James A. Bolognese +8 more
TL;DR: Rofecoxib, at doses 2-4 times the dose demonstrated to relieve symptoms of osteoarthritis, caused significantly less gastroduodenal ulceration than ibuprofen, with ulcer rates comparable to placebo.
Journal Article
Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
Elliot W. Ehrich,Glenn M. Davies,Douglas J. Watson,James A. Bolognese,Beth C. Seidenberg,Nicholas Bellamy +5 more
TL;DR: In this analysis, mean changes of roughly 9 to 12 mm (100 mm normalized visual analog scale, VAS) on WOMAC scales were perceptible changes to patients with hip and knee OA.